Iovance Biotherapeutics, Inc. (IOVA)
8.79
+0.09
(+1.03%)
USD |
NASDAQ |
Sep 04, 16:00
8.75
-0.04
(-0.46%)
After-Hours: 20:00
Iovance Biotherapeutics SG&A Expense (TTM) : 149.18M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 149.18M |
| March 31, 2026 | 147.60M |
| December 31, 2025 | 152.58M |
| September 30, 2025 | 158.68M |
| June 30, 2025 | 163.68M |
| March 31, 2025 | 165.55M |
| December 31, 2024 | 153.02M |
| September 30, 2024 | 140.42M |
| June 30, 2024 | 127.83M |
| March 31, 2024 | 110.19M |
| December 31, 2023 | 106.92M |
| September 30, 2023 | 103.48M |
| June 30, 2023 | 104.40M |
| March 31, 2023 | 108.81M |
| December 31, 2022 | 104.10M |
| September 30, 2022 | 101.48M |
| June 30, 2022 | 94.48M |
| March 31, 2022 | 87.46M |
| December 31, 2021 | 83.66M |
| September 30, 2021 | 75.90M |
| June 30, 2021 | 70.93M |
| March 31, 2021 | 65.97M |
| December 31, 2020 | 60.21M |
| September 30, 2020 | 55.00M |
| June 30, 2020 | 49.11M |
| Date | Value |
|---|---|
| March 31, 2020 | 45.63M |
| December 31, 2019 | 40.85M |
| September 30, 2019 | 37.50M |
| June 30, 2019 | 34.59M |
| March 31, 2019 | 30.55M |
| December 31, 2018 | 28.43M |
| September 30, 2018 | 26.28M |
| June 30, 2018 | 23.76M |
| March 31, 2018 | 20.86M |
| December 31, 2017 | 18.15M |
| September 30, 2017 | 17.80M |
| June 30, 2017 | 23.71M |
| March 31, 2017 | 27.04M |
| December 31, 2016 | 25.60M |
| September 30, 2016 | 24.51M |
| June 30, 2016 | 16.67M |
| March 31, 2016 | 11.79M |
| December 31, 2015 | 12.26M |
| September 30, 2015 | 11.51M |
| June 30, 2015 | 11.30M |
| March 31, 2015 | 10.67M |
| December 31, 2014 | 9.336M |
| September 30, 2014 | 7.136M |
| June 30, 2014 | 7.147M |
| March 31, 2014 | 6.177M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Amgen, Inc. | 7.019B |
| AVITA Medical, Inc. | 81.89M |
| Halozyme Therapeutics, Inc. | 238.00M |
| Neurocrine Biosciences, Inc. | 1.352B |
| Editas Medicine, Inc. | 45.51M |